Price
No data yet.
Social Signal Score
Revenue
$343.6K-43.74%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Shankar Hariharan
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Employees
- 9
- Beta
- 3.98
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 1.41
Financials
Revenue
$343.6K-43.7%Net Income
$-2.82MEBITDA
$-2.70MFree Cash Flow
$-3.13MEPS (diluted)
$-1.75Shares Outstanding (diluted)
1.58M+11178.5%Operating Expenses
$3.04MCash & Debt
$8.19MReturn of Capital
$0.00Dividend per Share
$37.50Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $431.6K | $-41.51M | $-67.50 |
| 2024 | $136.6K | $9.07M | $67.25 |
| 2023 | $1.36M | $-17.84M | $-583.75 |
| 2022 | $10.25M | $-3.47M | $-153.75 |
| 2021 | $9.89M | $-5.32M | $-245.00 |
| 2020 | $17.12M | $-2.54M | $-123.50 |
| 2019 | $7.44M | $-284.4K | $-18.00 |
| 2018 | $3.83M | $9.0K | $0.63 |
| 2017 | $2.93M | $289.0K | $22.50 |
| 2016 | $2.48M | $-2.76M | $-196.75 |
| 2015 | $2.91M | $-1.12M | $-80.25 |
| 2014 | $1.50M | $-2.01M | $-151.75 |
| 2013 | $955.9K | $-2.09M | $-333.75 |
| 2012 | $806.0K | $-150.7K | $0.00 |
Valuation
SCNXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·4d ago·Neutral
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals Major Institutional Formulary Win Expands Arbli ™ 's Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially
View source ↗ - Newsglobenewswire.com·5d ago·Neutral
Scienture Holdings, Inc. Announces Reverse Stock Split COMMACK, NY, Sept. 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that it has determined to effect a reverse stock sp…
View source ↗ - Newsglobenewswire.com·14d ago·Neutral
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner Agreement provides dedicated commercial channel for REZENOPY ™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United States
View source ↗ - Newsglobenewswire.com·53d ago·Negative
…e Company's Second Commercial Product and Expanding Its Revenue-Generating Portfolio COMMACK, NY, Aug. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and r…
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray Commercial launch supported by a dedicated national sales force, payer and institutional access, and multi-channel marketing campaign supporting adoption of REZENOPY ™
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.06 per share
Typical surprise +87.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.07 vs $-0.09beat
- Mon, May 11$-0.08 vs $-5.75beat
- Tue, Mar 24$-1.76 vs $-5.50beat
- Wed, Nov 12$-0.19 vs $-3.75beat
- Mon, Aug 11$-0.48 vs $-3.75beat
- Mon, May 12$-0.33 vs $-3.75beat
Estimates and results for SCNX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SCNX officers and directors.
No open-market trades in the recent filings. All 16 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
16 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SCNX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.